Val
—
Gro
—
Qua
—
Mom
—
Sta
—
Cap—
P/S2.97
P/E—
Fwd P/E12.53
PEG0.63
52W— – —
RSI—
Target$62.41 (+45.3%)
Beta0.57
Div—
Loading chart…
RSI ()
Loading patterns…
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in two segments, MedSurg and Cardiovascular. It offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, SpyGlass, single-use scopes used for diagnostic and therapeutic procedures in the pancreaticobiliary system, in endoscopic retrograde cholangiopancreatography procedures, and single-use duodenoscopes, as well as endoluminal surgery and infection prevention products; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, urinary and bowel dysfunction, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, penile implants, artificial urinary sphincter, laser system, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator systems, radiofrequency ablation, and intraosseous nerve ablation and deep brain stimulation systems. The company also provides technologies for diagnosing and treating a range of diseases and abnormalities of the heart; WATCHMAN FLX, a left atrial appendage closure (LAAC) device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, it offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose and treat forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
Signal
Trend Strength
Price Levels
52-Week Range
52W Low
—
52W High
Position in Range
—
RSI (14)
0 · Oversold
RSI 33
Overbought · 100
Signal
Neutral
EMA Price Levels
Activity & Patterns
Volume Analysis
Momentum Dashboard
Detected Patterns
4Bullish
7Bearish
0Neutral
Key Signals 2
▲ Double Bottom
Major reversal
2026-07-31 · $46.37
Two lows ~$42.23 — bullish reversal confirmed
Learn more →
▼ Head & Shoulders
Major reversal
2026-09-10 · $44.15
H&S neckline ~$44.15 broken — major bearish reversal
Learn more →
Momentum Signals 9
▲ MACD Bullish Crossover
▲ MACD Bullish Crossover
▲ Bull Flag
▼ MACD Bearish Crossover
View overlays on the price chart via Overview tab → Pattern Overlays.
EPS — History & Forecast
Estimate
Beat
Miss
Forecast
Loading…
Revenue — History & Forecast
Revenue
Forecast
Loading…
EPS Beat Rate
100%
8/8 quarters
Wall Street Consensus
BUY
BuyHoldSell
Price Target Range
$62.41
+45.3% upside
Low $44
—
High $94
Consensus
Current price
Wall Street Analyst Ratings
Sort by
| Firm | Rating | Change | Action | Date |
|---|
Profitability
Gross Margin
69.19%Last 12 Months
Operating Margin
22.90%Last 12 Months
Return on Equity
15.34%Last 12 Months
Revenue Growth
7.50%Year over Year
Free Cash Flow
2.45BLast 12 Months
Free Cash Flow Yield
—Last 12 Months
Balance Sheet
Debt / Equity
50.15Most Recent Quarter
Current Ratio
1.24Most Recent Quarter
Cash
539.00MMost Recent Quarter
Total Debt
12.62BMost Recent Quarter
Net Debt
—Most Recent Quarter
How BSX Makes Its Money
Cash Flow Breakdown
Quarterly Metrics
| Quarter | Revenue | Rev YoY | Gross Profit | Op. Income | Net Income | Net YoY | Gross % | Op % | Net % |
|---|
Full Key Statistics
Valuation
| Market Cap | 62.29B |
| Enterprise Value | 74.61B |
| Trailing P/E | 17.40 |
| Forward P/E | 12.53 |
| PEG Ratio (5yr) | 0.63 |
| Price/Sales (ttm) | 2.97 |
| Price/Book (mrq) | 2.49 |
| EV/Revenue | 3.55 |
| EV/EBITDA | 13.06 |
Share Statistics
| Avg Vol (3m) | 20.00M |
| Shares Outstanding | 1.45B |
| Float | 1.44B |
| % Held by Insiders | 0.25% |
| % Held by Institutions | 94.76% |
| Short Ratio | 2.48 |
| Short % of Float | 3.33% |
Profitability
| Gross Margin | 69.19% |
| Operating Margin (ttm) | 22.90% |
| Profit Margin | 17.50% |
| Return on Assets (ttm) | 6.19% |
| Return on Equity (ttm) | 15.34% |
Income Statement
| Revenue (ttm) | 21.00B |
| Revenue Growth (yoy) | 7.50% |
| Gross Profit (ttm) | 14.53B |
| EBITDA | 5.71B |
| Net Income (ttm) | 3.67B |
| Diluted EPS (ttm) | 2.47 |
| EPS Growth (yoy) | 15.10% |
Balance Sheet
| Total Cash (mrq) | 539.00M |
| Total Debt (mrq) | 12.62B |
| Debt / Equity (mrq) | 50.15 |
| Current Ratio (mrq) | 1.24 |
| Book Value / Share | 17.23 |
| Operating CF (ttm) | 4.53B |
| Free Cash Flow (ttm) | 2.45B |
Trading & Dividends
| Beta (5Y) | 0.57 |
| 50-Day MA | 46.94 |
| 200-Day MA | 65.96 |
| Fwd Dividend Yield | N/A |
| Payout Ratio | 0.00% |
No dividend history available for BSX.
Ownership Breakdown
Institutional 94.76%
Insider 0.25%
Public 5.0%
Short Interest
3.33% of float
Moderate
Institutional 13F Holdings
Famous investors who disclosed a position in BSX in their latest SEC 13F filing.
Loading…
Insider Transactions
| Date | Insider | Role | Transaction | Shares | Price | Value |
|---|